Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) gapped up before the market opened on Wednesday. The stock had previously closed at $8.57, but opened at $10.03. Capricor Therapeutics shares last traded at $9.65, with a volume of 11,387,103 shares.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CAPR. Wall Street Zen lowered Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Piper Sandler raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, September 1st. Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a research note on Thursday, September 17th. Alliance Global Partners cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a report on Tuesday, July 28th. Finally, Roth Capital cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a report on Monday, July 27th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Capricor Therapeutics has an average rating of “Hold” and an average price target of $30.25.

Capricor Therapeutics Stock Up 12.7%

The stock has a market capitalization of $561.52 million, a PE ratio of -3.93 and a beta of 0.72. The business’s 50-day moving average is $8.15 and its two-hundred day moving average is $21.51.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). As a group, analysts anticipate that Capricor Therapeutics, Inc. will post -1.71 EPS for the current year.

Institutional Trading of Capricor Therapeutics

Large investors have recently made changes to their positions in the company. Montanova Capital LLC grew its stake in Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after buying an additional 274,184 shares during the last quarter. Bank of America Corp DE lifted its stake in Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after buying an additional 361,664 shares during the last quarter. SB Capital Management Inc purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $11,544,000. Walleye Capital LLC acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $5,397,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at approximately $3,895,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.